ReviewInternational journal of nanomedicine2025
Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.International journal of nanomedicine · 2026Review
- Nanoplatforms-Enhanced High-Intensity Focused Ultrasound for Cancer Immunotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal primary liver malignancies worldwide. Despite significant advances in surgical resection and local ablation therapies, challenges such as low early detection rates, high postoperative recurrence, and limited local tumor control persist in clinical practice. In recent years, the rapid advancement of nanobiotechnology has opened new avenues for precise diagnosis and personalized therapy of HCC. Owing to their excellent biocompatibility and functional tunability, various nanocarriers have been extensively explored in ablation-based treatments to achieve targeted drug delivery, controlled release, enhanced image guidance, and immune modulation. These innovations have substantially improved both the efficacy and safety of ablation therapies. This review focuses on recent progress in the application of nanobiotechnology to HCC ablation, systematically summarizing its mechanisms, innovative strategies, and future prospects across radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation (CRA), high-intensity ultrasound focused ablation (HIFU), irreversible electroporation (IRE) and photothermal therapy (PTT). This review aims to comprehensively summarize recent advances in the application of nanobiomaterials-biocompatible and functionally engineered nanomaterials-in ablation-based therapies for HCC, emphasizing their roles in enhancing therapeutic efficacy, imaging guidance, and immune modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.